Site Overlay

Clinical Application of SPECT-CT Imaging with 99mTc-PSMA in Patients with Recurrent Prostate Cancer

By Boris

Volume 9, Issue 1

Original Article / Published: November 2021

DOI: https://www.doi.org/10.57045/jemis/911121.pp17-28

S. Sergieva (1), R. Mangaldgiev (2), M. Dimchevaм (1), V. Parvanova (3), K. Nedev (4), Z. Zahariev (5), B. Robev (6), O. Gatsev (7), K.Petkova (7), I. Saltirov (7)

  1. Department of Nuclear Medicine, Sofia Cancer Center, Sofia
  2. Department of Medical Oncology, Sofia Cancer Center, Sofia
  3. Department of Radiotherapy, National Oncological Centre, Sofia
  4. Department of Radiotherapy, Acibadem City Clinic, Sofia
  5. Department of Radiotherapy, Uni Hospital, Panagyurishte
  6. Department of Medical Oncology, UH “St Ivan Rilsky”, Sofia
  7. Department of Urology and Nephrology, Military Medical Academy, Sofia Bulgaria

Abstract

Introduction: Prostate cancer is the most common malignancy in men in Europe. One of the important clinical problems is the early detection and visualization of recurrence after radical prostatectomy, radiation therapy or other radical topical treatment, in patients with PSA values above 0.2 ng/ml. With the introduction of molecular highly sensitive imaging methods after administration of radiolabeled prostate-specific membrane antigen (PSMA), it became possible to detect early functional changes associated with the development of a metastatic process in this disease, with a negative CT or MRI result. 99mTc-PSMA is a new radiopharmaceutical and is a small ligand that binds to the active core of PSMA. The aim of our study was to evaluate the clinical role of 99mTc-PSMA in imaging local recurrence and/or loco-regional and distant metastases in patients with recurrent prostate cancer and biochemical disease progression. Material and methods: A cohort of 36 prostate cancer patients was evaluated with established laboratory data for biochemical progression of the disease – increase in the serum value of the tumour marker PSA and its doubling time within 6 months. In 3/36 of the patients, prostate adenocarcinoma was accidentally detected after transurethral resection of the prostate. Hormonal and cytoreductive radiotherapy was performed in these patients as a therapy. The remaining 33/36 patients underwent radical treatment of primary cancer after a systematic MRI/US fusion prostate biopsy. Results: All of these patients underwent a whole body scan followed by a targeted SPECT-CT study, 1–3 hours after intravenous administration of 99mTc-PSMA. The sensitivity of the SPECT-CT test with 99mTc-PSMA for the detection of recurrent prostate cancer in 36 followed patients was 84.37% (27/32), specificity – 100% (4/4) and accuracy – 86.11% 31/36). Conclusion: For the clinical application of 99mTc-PSMA SPECT-CT we can summarize that this method finds the greatest clinical application for early diagnosis of recurrent disease in patients with prostate cancer and biochemical progression, at serum PSA levels ≥0.50 ng / ml, in order to determine a personalized treatment for each individual patient.

 

References

  1. Ferlay J, 2018 Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. EJC2018; 103: 356-387.
  2. European Cancer Information System-ECIS, European Commission 2018, https://ecis.jrc.ec.europa.eu/, accessed on 12 March 2019.
  3. Gary J. Kelloff, Peter Choyke, and Donald S. Coffey. Challenges in Clinical Prostate Cancer: Role of Imaging. American Journal of Roentgenology 2009 192:6, 1455-1470
  4. Engelbrecht MR, Jager GJ, Laheij RJ, Verbeek AL, van Lier HJ, Barentsz JO. Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis. Eur Radiol. 2002 Sep;12(9):2294-302. doi: 10.1007/s00330-002-1389-z. Epub 2002 Apr 19. PMID: 12195484.
  5. Hillier SM, Maresca KP, Lu G, Merkin RD, Marquis JC, Zimmerman CN, et al. 99mTc-labeled small-molecule inhibitorsof prostate-specific membrane antigen for molecular imaging ofprostate cancer. J Nucl Med. 2013;54:1369–76.
  6. von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G. 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol Focus. 2018 Sep;4(5):686-693. doi: 10.1016/j.euf.2016.11.002.
  7. Hupe MC, Philippi C, Roth D, Kümpers C, Ribbat-Idel J, Becker F, et al Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis.Front Oncol. 2018 Dec 20;8:623
  8. Oliveira JM, Gomes C, Faria DB, Vieira TS, Silva FA, Vale J, et al. 68Ga-prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Prostate Cancer Imaging: A Narrative Literature Review. World J Nucl Med. 2017;16:3–7
  9. Kratochwil C, Giesel FL, Stefanova M, Benešová M, Bronzel M, Afshar-Oromieh A, et al. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617. J Nucl Med. 2016 Aug;57(8):1170-6. doi: 10.2967/jnumed.115.171397. Epub 2016 Mar 16. PMID: 26985056. .
  10. Jones W., Griths K., Barata P.C., Paller C. J. PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy. Cancers 2020, 12, 1367; doi:10.3390/cancers12061367.
  11. Schwarzenboeck SM, Rauscher I, Bluemel C, Fendler WP, RoweSP, Pomper MG, et al. PSMA ligands for PET imaging of prostatecancer. J Nucl Med. 2017;58:1545–52.
  12. Beheshti M, Manafi-Farid R, Geinitz H, Vali R, Loidl W, Mottaghy FM, etal. 68Ga-PSMA PET/CT in the Detection of Early Recurrence in Prostate Cancer Patients with a PSA Level of Less Than 1 ng/mL: A Prospective Study of 135 Patients. J Nucl Med. 2020 Oct;61(10):1484-1490. doi: 10.2967/jnumed.119.238071.
  13. Krimphove MJ, Theissen LH, Cole AP, Preisser F, Mandel PC, Chun FKH. Performance and Impact of Prostate Specific Membrane Antigen-Based Diagnostics in the Management of Men with Biochemical Recurrence of Prostate Cancer and its Role in Salvage Lymph Node Dissection. World J Mens Health. 2020 Jan;38(1):32-47. doi: 10.5534/wjmh.180133.
  14. Mariani G, Bruselli L, Kuwert T, Kim EE, Flotats A, Israel O, et al. A review on the clinical uses of SPECT/CT. Eur J Nucl Med Mol Imaging 2010;37:1959-85.
  15. Albalooshi B, Al sharhan M, Bagheri F, Miyanath Sh, Ray B, Muhasin M, Zakavi SR. Direct comparison of 99mTc-PSMA SPECT/CT and 68Ga-PSMA PET/CT in patients with prostate cancer.Asia Ocean J Nucl Med Biol. 2020; 8(1):1-7. doi: 10.22038/aojnmb.2019.43943.1293.
  16. Rauscher I, Maurer T, Beer AJ, Graner FP, Haller B, Weirich G, et al. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2016 Nov;57(11):1713–9.
  17. Lawal IO, Ankrah AO, Mokgoro NP, Vorster M, Maes A, Sathekge MM. Diagnostic sensitivity of 99m Tc- HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with 68Ga- PSMA PET/CT. The Prostate. 2017 Aug;77(11):1205–12.
  18. Schmidkonz C, Hollweg C, Beck M, Reinfelder J, Goetz TI, Sanders JC, et al. 99m Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer. Prostate 2018;78:54-63.
  19. iu C, Zhu Y, Su H, Xu X, Zhang Y, Ye D, et al. Relationship between PSA kinetics and Tc-99m HYNIC PSMA SPECT/ CT detection rates of biochemical recurrence in patients with prostate cancer after radical prostatectomy. Prostate 2018;78: 1215-21.
  20. Goffin KE, Joniau S, Tenke P, et al: Phase 2 study of99mTc-Trofolastat SPECT/CT to identify andlocalize prostate cancer in intermediate- and high-risk patientsundergoing radical prostatectomy and extended pelvic LN dissection. J Nucl Med 58:1408-1413, 2017.
  21. Trabulsi EJ, Rumble RB, Jadvar H, Hope T, Pomper M, Turkbey B, et al. Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline. J Clin Oncol. 2020 Jun 10;38(17):1963-1996. doi: 10.1200/JCO.19.02757.
  22. Maurer T, Robu S, Schottelius M, Schwamborn K, Rauscher I, van den Berg NS, van Leeuwen FWB, Haller B, Horn T, Heck MM, Gschwend JE, Schwaiger M, Wester HJ, Eiber M. 99mTechnetium-based Prostate-specific Membrane Antigen-radioguided Surgery in Recurrent Prostate Cancer. Eur Urol. 2019 Apr;75(4):659-666. doi: 10.1016/j.eururo.2018.03.013.
  23. Su HC, Zhu Y, Hu SL, Liu C, Lin GW, Dai B, Zhang YJ, Ye DW. The Value of 99mTc-PSMA SPECT/CT-Guided Surgery for Identifying and Locating Lymph Node Metastasis in Prostate Cancer Patients. Ann Surg Oncol. 2019 Feb;26(2):653-659. doi: 10.1245/s10434-018-6805-y. Epub 2018 Oct 15. PMID: 30324468.
Click to review Volume 9, Issue 1
Article [pdf]

Keywords:

Prostate cancer, recurrent prostate cancer, 99mTc-PSMA, SPECT-CT

How to cite this article:

S.Sergieva, R. Mangaldgiev, M. Dimcheva, V. Parvanova,K.Nedev, Z. Zahariev, B. Robev, O. Gatsev, K. Petkova, I.Saltirov. Clinical Application of SPECT-CT Imaging with99mTc-PSMA in Patients with Recurrent Prostate Cancer.Journal of Endourology and Minimally Invasive Surgery(Bulgaria) 2021; 9 (1): 17-28

Corresponding author:

Prof. Sonya Sergieva MD, Phd;

Head, Department of Nuclear Medicine, Sofia Cancer Center

Blvd. “Andrey Saharov”22, Sofia – 1784, Bulgaria

E-mail: sergieva.sonya@yahoo.com